Title
Category
Credits
Event date
Cost
  • LivDerm
  • TME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
$0.00
Hidradenitis suppurativa (HS), also called acne inversa, is an inflammatory disease characterized by recurring, painful abscesses, and fistulous tracts, and can impact adults and pediatric patients. Symptoms of HS include pain and scarring as well as psychological consequences, such as embarrassment, social isolation, and depression, and is associated with a poor quality of life. Several studies suggest that the prevalence of HS ranges from 0.00033 to 4.1%, although underdiagnosis or improper diagnosis is an issue. 
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), Additionally, the impact of commonly-used medications with high sodium content contributes to this burden.  As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including in patients with sleep disorders, as well as practical strategies to minimize the impact of elevated sodium.
  • TME
  • 0.50 AMA PRA Category 1 Credit
  • 0.50 Participation
$0.00
Eosinophilic esophagitis (EoE), a chronic, debilitating illness that is mediated via cells of the immune system (eosinophils) eliciting T-helper 2 (Th2) cell mediated inflammation, affects several people globally and imparts significant impact on the quality of life (QoL) of the affected patient population. Advanced disease can lead to esophageal tissue remodeling and dysfunction, underscoring the importance of prompt diagnosis. However, evidence suggests delayed diagnosis for EoE occurs frequently.
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Iron deficiency (ID) with or without anemia is a common comorbidity in patients with heart failure (HF), and it can have significant impacts on morbidity and mortality. Intravenous (i.v.) iron repletion in HF patients with ID can improve symptoms, quality of life, and outcomes, and this evidence has been reflected accordingly in HF guidelines, in addition to a recent FDA approval. During this activity, experts discuss the latest evidence and considerations about the screening, diagnosis, and treatment of ID in patients with HF.